Article info
Original research
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study
- Correspondence to Professor Sandro Pignata, Gynecological Oncology, National Cancer Institute, Naples, Italy; s.pignata{at}istitutotumori.na.it
Citation
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study
Publication history
- Received December 21, 2020
- Revision received April 6, 2021
- Accepted April 8, 2021
- First published May 14, 2021.
Online issue publication
July 05, 2021
Article Versions
- Previous version (14 May 2021).
- Previous version (3 June 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.